Io Biotech Inc (IOBT) Stock Price, Quote & News

Company Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 29 80

Website: www.iobiotech.com

Address:

Ole MaalOees Vej 3, Copenhagen N, Copenhagen, Denmark

Notnotshort Sep. 9 at 8:43 PM

$IOBT Dont know if I have already posted this? Ipi-Nivo had 54% ORR and 11.2 months mPFS in PDL1-. Lots of horsepower, while Nivo-Rela had 37.3% and got to 6.4 months mPFS. Sooo, we got 16 months of mPFS, however we had lower n, that could be an advantage if we had easier patients, but we dont know how well this group was balanced in regard to other negative prognostic factors. I would say that 16 months is still brutal if you compare this to the competition at basically 0 additional systemic toxicity. Cant believe this POS does not move up.

0 · Reply

Notnotshort Sep. 9 at 6:52 PM

$IOBT According to CMO OS benefit seen in basically all subgroups, except for the anti-pd1 experienced obviously. So the PFS benefit seen in subgroups translates into OS benefit, which is what you would expect from immunotherapy in melanoma, and the FDA knows this. you get a combo therapy with combo efficacy with toxicity of single agent anti-pd1 therapy. Durability of responses seen in Head and neck and as I understood him also seen in the PH3 melanoma trial. From the data they have shared so far the responses are very durable. There also needs to be a big ORR difference in PDL1-, cause with median PFS of 3 months you cant have 50% ORR when working with anti-pd1, so probably something in the 30-35% range for the control arm. To get to 12 months mPFS you would need need close to 50% with high durability, which is unlikely just from anti-pd1 with n>60. to get to 16 months you will probably need something like 55% and great durability.

1 · Reply

GCPA Sep. 9 at 6:40 PM

$IOBT By the way, they don't seem to want to be precise about timing of OS data: "somewhere in 2026", said today the CMO when asked (he also mentiones they had analyzed the trend the curves show). Are they not sure about data being ready in 1H 2026? If data cut-off were in the middle of June, it meant 12 months more of follow-up to reach 27 events more. Just Pembro arm should reach them in 12 months if it repllicated Keynote-006. Intriguing...

0 · Reply

outlawinvestor1 Sep. 9 at 4:21 PM

$IOBT that was an excellent fireside chat and great review below. they do make it clear that they will need to raise likely before end of year. positive fda response is the catalyst they need for a good offering.

0 · Reply

badprecog Sep. 9 at 3:41 PM

$IOBT Said they were also going to submit to Europe this year as well.

1 · Reply

badprecog Sep. 9 at 2:48 PM

$IOBT Said she was still filing a BLA this year.

0 · Reply

nikitatrades Sep. 9 at 1:44 PM

$IOBT #IOBiotech's lead drug, IO102-103 (Cylembio), showed strong PFS of 19.4m vs 11m in a Phase III melanoma trial. Missed p-value but co. plans to submit for FDA approval by EOY based on "totality of data" & safety. Cash into Q1 2026. ⚕️🧬 #Biotech

0 · Reply

GCPA Sep. 9 at 12:49 PM

$IOBT This is the paper she quoted (JAMA, 2021) "Between 2018 and 2021, the FDA approved 210 new drugs, 21 (10.0%) based on pivotal studies with null findings for 1 or more primary efficacy end points (Table 1). These 21 drugs were approved for 21 unique clinical indications. Of these drugs, 11 (52.4%) were first in class, 10 (47.6%) received orphan designation, and 14 (66.7%) received an expedited review designation. Before approval, an advisory committee was convened for 3 (14.3%) of the drugs." https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2801023

2 · Reply

GCPA Sep. 9 at 12:25 PM

$IOBT some tips from the MS meeting: 1) They insisted many times in their risk/benefit balance (appealing to FDA flexibility). CEO even mentioned a paper publised in JAMA (2023 apparently) which says that 10% of approved drugs had failed stat sig. 2) Importantly, the FDA team they will discuss with is the same that has accompanied them since the BTD. 3) Update about FDA meeting outcome in "a month or two". 4) Late-braking abstract for full dataset already accepted in a conference. It must be ESMO then. 5) Used the word "partnership" when talking about launch. 6) Prelim data of Neoadjuvant/Adjuvant EARLE next year. OS data somewhere in 2026.

6 · Reply

GCPA Sep. 8 at 8:54 PM

$IOBT In the meanwhile, while we wait for FDA meeting. What is now really intriguing for me is the number of events for OS Final analysis. If instead of 169 events (27 more), they could wait for 182 (40 more), stat sig could change dramatically (for good, if the trend continues as it looks like). We are talking about very few patients. 27 events more means 16% of total 169 events; 40 means 22% of total 182 events. The weight of coming OS events over the total will increase a lot just with a bunch more.

2 · Reply

IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 8:05 AM EDT - 5 days ago

IO Biotech Announces Participation in Upcoming Investor Conferences

Aug 14, 2025, 4:05 PM EDT - 26 days ago

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 12, 2025, 4:17 PM EDT - 4 weeks ago

IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma

Aug 11, 2025, 8:24 AM EDT - 4 weeks ago

IO Biotech's cancer vaccine shows improvement in late-stage study goal

Aug 11, 2025, 8:00 AM EDT - 4 weeks ago

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Aug 10, 2025, 8:00 AM EDT - 4 weeks ago

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

May 20, 2025, 8:05 AM EDT - 4 months ago

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

May 14, 2025, 8:05 AM EDT - 4 months ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Apr 26, 2025, 3:05 PM EDT - 4 months ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 4 months ago

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

Mar 25, 2025, 4:35 PM EDT - 6 months ago

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 18, 2025, 8:00 AM EDT - 6 months ago

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

Mar 4, 2025, 4:17 PM EST - 6 months ago

IO Biotech Reports 2024 Business Highlights

Feb 23, 2025, 12:07 PM EST - 7 months ago

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

Feb 20, 2025, 8:05 AM EST - 7 months ago

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Feb 4, 2025, 8:05 AM EST - 7 months ago

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Jan 9, 2025, 8:05 AM EST - 8 months ago

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Dec 20, 2024, 8:05 AM EST - 9 months ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Nov 12, 2024, 7:05 AM EST - 10 months ago

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 7, 2024, 10:00 AM EST - 10 months ago

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

Oct 4, 2024, 9:00 AM EDT - 1 year ago

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 14, 2024, 2:30 AM EDT - 1 year ago

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Aug 30, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Aug 13, 2024, 7:05 AM EDT - 1 year ago

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 25, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

May 23, 2024, 8:30 AM EDT - 1 year ago

IO Biotech to Present at Jefferies Global Healthcare Conference

May 14, 2024, 7:55 AM EDT - 1 year ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 24, 2024, 4:30 PM EDT - 1 year ago

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Apr 5, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Mar 6, 2024, 4:11 PM EST - 1 year ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:40 PM EST - 1 year ago

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Feb 26, 2024, 4:05 PM EST - 1 year ago

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Jan 3, 2024, 3:04 AM EST - 1 year ago

IO Biotech: A Phase 3 Company Getting No Respect

Dec 21, 2023, 8:30 AM EST - 1 year ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Nov 13, 2023, 8:12 AM EST - 1 year ago

IO Biotech Announces 2023 Third Quarter Results

Nov 13, 2023, 8:00 AM EST - 1 year ago

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Nov 10, 2023, 8:00 AM EST - 1 year ago

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Nov 1, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 23, 2023, 1:00 AM EDT - 2 years ago

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Soci

Oct 3, 2023, 4:30 PM EDT - 2 years ago

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 12, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

Aug 11, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Announces 2023 Second Quarter Results

Aug 11, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Appoints Heidi Hunter to its Board of Directors

Aug 8, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

Aug 7, 2023, 8:30 AM EDT - 2 years ago

IO Biotech, Inc. Announces $75 Million Private Placement Financing

Jul 28, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

Jul 25, 2023, 4:05 PM EDT - 2 years ago

IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer

Notnotshort Sep. 9 at 8:43 PM

0 · Reply

Notnotshort Sep. 9 at 6:52 PM

1 · Reply

GCPA Sep. 9 at 6:40 PM

0 · Reply

outlawinvestor1 Sep. 9 at 4:21 PM

0 · Reply

badprecog Sep. 9 at 3:41 PM

$IOBT Said they were also going to submit to Europe this year as well.

1 · Reply

badprecog Sep. 9 at 2:48 PM

$IOBT Said she was still filing a BLA this year.

0 · Reply

nikitatrades Sep. 9 at 1:44 PM

0 · Reply

GCPA Sep. 9 at 12:49 PM

2 · Reply

GCPA Sep. 9 at 12:25 PM

6 · Reply

GCPA Sep. 8 at 8:54 PM

2 · Reply

Bullbi Sep. 8 at 8:11 PM

$IOBT what’s our wishlist for the conference tomorrow am?

1 · Reply

Bullbi Sep. 8 at 4:29 PM

$IOBT nice retrace of all our gains from last friday, super sick 😭

1 · Reply

Notnotshort Sep. 7 at 7:40 PM

$IOBT More data from SMMT and found this exchange with Adam Feuerstein. @GCPA they put a lot of weigh on pre-specified analysis. If these idiots would have pre-specified an analysis for naive man, cant believe these clowns didnt do that with 0 data for the anti-PD1 experienced patients. Complete morons https://x.com/LY4101174/status/1964635133820145752

3 · Reply

GFstocktwits Sep. 6 at 1:13 AM

$IOBT So with a 507 patient statistical FAIL = NOT significant re Cylembio and Keytruda, it should be on teh way back to 1.50 and below and the price was 1.50 BEFORE the -ve news came out

3 · Reply

somaopp Sep. 5 at 7:45 PM

$IOBT too close??

0 · Reply

Love_To_Learn Sep. 5 at 7:34 PM

$RETO chain link 1.89 $IOBT 1.89/1.90 access to $SLS

0 · Reply

Love_To_Learn Sep. 5 at 7:30 PM

$IOBT using u to guide $SLS lil push temp 4 this window n sequence 1 min chart

0 · Reply

Love_To_Learn Sep. 5 at 6:40 PM

$IOBT minor pivot on u for $SLS touch step

1 · Reply

badprecog Sep. 5 at 2:07 PM

$IOBT interesting… cat out of bag? I wonder how stick $2 will be?

2 · Reply

Notnotshort Sep. 5 at 1:08 PM

$IOBT This is the PFS chart from Relativity 47 stratified by PDL1 status. The PDL1- chart looks incredible, big difference between curves and thats a HR of 0.66. Imagine how our chart looks like with HR of 0.54. HR of 0.54 means that you more than double progression free-survival compared to the control arm. In Pembro arm 22% are progression free, while in Cylembio arm 49% are progression free with 18 months of minimum follow-up. What comes after 1L treatment? ICI again, TILs, Ipi single agent, BRAF inhibitors and IL2 high dose. Mostly nasty shit thats very ineffective in 2nd. TILs seem to be the best options, but only around 25% are eligable in 2nd line. It certainly gets very hopeless after 1L failure and you haave to endure a lot of shit to prolong live with low QOL. TILs give hope for durable responses, but the treatment is brutal and can kill you, even when you are young and relatively fit.

2 · Reply

DrUpUpAway Sep. 5 at 9:34 AM

$IOBT I notice chatter now of Private Placements? Partnerships? Dilution!?? Instead l give you ‘Dr Ups Reasonable Merck Buyout Scenario’. Zocca’s recent golden parachute amended contract is evidence of possible buyout. Merck can build the ultimate Opdualag. With best in class Keytruda and Mads Magic Cylembio, new product new patent. The ultra conservative case: We get BLA label for PDL1neg patients. Modeling Cylembio on USA only melanoma PDL1neg 12% market penetration (88% other therapy) 5000 annual patients. At $ 125k (75% opdualag drug price). Total 3 year ramped up revenue is $ 1B (annual peak $ 500Mil). Conservative again 2x peak sales multiple is $ 1B buyout. Now about $IOBT shares. 66M outstanding. 9M warrants floating around including EIB’s third tranche. Total 75M fully diluted. BUYOUT PRICE: $ 13 PER SHARE. So there you have it. The deal of the year for Merck.. and it seems they are looking for deals this year. This is What If Speculation I'm overlooking many factors.

3 · Reply

badprecog Sep. 4 at 10:46 PM

$IOBT This will go full pirate mode once full BLA is announced

1 · Reply

Market Cap	128.47M
Revenue (ttm)	0.00
Net Income (ttm)	-95.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	4.23

Volume	595,200
Avg Vol	3,861,968
Day's Range	N/A - N/A
Shares Out	65.88M
Stochastic %K	57%
Beta	0.41
Analysts	Strong Sell
Price Target	$9.00